Clinical Trial Detail

NCT ID NCT02097810
Title Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. (STARTRK-1)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Hoffmann-La Roche
Indications

Advanced Solid Tumor

Therapies

Entrectinib

Age Groups: adult senior

Additional content available in CKB BOOST